On December 15, biopharmaceutical company Sanofi announced a strategic cooperation with DrenBio. The two sides will jointly discover and develop next-generation B-cell depletion treatments for various autoimmune diseases. Of this, DrenBio will receive $100 million in advance and be eligible for future development, regulatory, and commercial milestone payments of up to $1.7 billion. This new partnership builds on Sanofi's previous acquisition of DR-0201 assets.

Zhitongcaijing · 1d ago
On December 15, biopharmaceutical company Sanofi announced a strategic cooperation with DrenBio. The two sides will jointly discover and develop next-generation B-cell depletion treatments for various autoimmune diseases. Of this, DrenBio will receive $100 million in advance and be eligible for future development, regulatory, and commercial milestone payments of up to $1.7 billion. This new partnership builds on Sanofi's previous acquisition of DR-0201 assets.